Cargando…

Clinical investigation of a unique type of hypothalamic adrenal insufficiency

Hypothalamic adrenal insufficiency (AI) is a rare but distinct type of AI. The leading cause of hypothalamic AI is a secondary side-effect of exogenous steroid intake, particularly in large amounts and/or long-term periods. The next cause would be the effect of the tumor in the hypothalamic lesions....

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, Kaori, Abe, Ichiro, Nagata, Mai, Ochi, Kentaro, Senda, Yuki, Koga, Midori, Ohe, Kenji, Abe, Makiko, Kudo, Tadachika, Kobayashi, Kunihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575774/
https://www.ncbi.nlm.nih.gov/pubmed/36253985
http://dx.doi.org/10.1097/MD.0000000000030597
_version_ 1784811384862670848
author Takeshita, Kaori
Abe, Ichiro
Nagata, Mai
Ochi, Kentaro
Senda, Yuki
Koga, Midori
Ohe, Kenji
Abe, Makiko
Kudo, Tadachika
Kobayashi, Kunihisa
author_facet Takeshita, Kaori
Abe, Ichiro
Nagata, Mai
Ochi, Kentaro
Senda, Yuki
Koga, Midori
Ohe, Kenji
Abe, Makiko
Kudo, Tadachika
Kobayashi, Kunihisa
author_sort Takeshita, Kaori
collection PubMed
description Hypothalamic adrenal insufficiency (AI) is a rare but distinct type of AI. The leading cause of hypothalamic AI is a secondary side-effect of exogenous steroid intake, particularly in large amounts and/or long-term periods. The next cause would be the effect of the tumor in the hypothalamic lesions. We show here 9 cases of hypothalamic AI without any disorder on imagings and a history of steroid administration. All patients had general fatigue; 7 patients (77.8%) had a history of hypoglycemia; 5 patients (55.6%) had a history of hypotension. None of the patients had hyponatremia, hyperkalemia, or eosinophilia. Their morning plasma adrenocorticotropic hormone (ACTH) value was low at 8.5 ± 4.2 pg/mL, and serum cortisol value was low at 4.5 ± 1.3 µg/dL. All patients demonstrated normal responses during the corticotropin-releasing hormone loading (CRH) test but inadequate responses during the insulin tolerance test (ITT). After hydrocortisone replacement therapy, their morning plasma ACTH and serum cortisol values were significantly recovered (P < .05). Moreover, more than half of the patients were fine after discontinuing hydrocortisone replacement therapy. These results indicate that this unique type of hypothalamic AI has a curable clinical course making hydrocortisone replacement therapy a novel therapeutic option.
format Online
Article
Text
id pubmed-9575774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95757742022-10-17 Clinical investigation of a unique type of hypothalamic adrenal insufficiency Takeshita, Kaori Abe, Ichiro Nagata, Mai Ochi, Kentaro Senda, Yuki Koga, Midori Ohe, Kenji Abe, Makiko Kudo, Tadachika Kobayashi, Kunihisa Medicine (Baltimore) 4300 Hypothalamic adrenal insufficiency (AI) is a rare but distinct type of AI. The leading cause of hypothalamic AI is a secondary side-effect of exogenous steroid intake, particularly in large amounts and/or long-term periods. The next cause would be the effect of the tumor in the hypothalamic lesions. We show here 9 cases of hypothalamic AI without any disorder on imagings and a history of steroid administration. All patients had general fatigue; 7 patients (77.8%) had a history of hypoglycemia; 5 patients (55.6%) had a history of hypotension. None of the patients had hyponatremia, hyperkalemia, or eosinophilia. Their morning plasma adrenocorticotropic hormone (ACTH) value was low at 8.5 ± 4.2 pg/mL, and serum cortisol value was low at 4.5 ± 1.3 µg/dL. All patients demonstrated normal responses during the corticotropin-releasing hormone loading (CRH) test but inadequate responses during the insulin tolerance test (ITT). After hydrocortisone replacement therapy, their morning plasma ACTH and serum cortisol values were significantly recovered (P < .05). Moreover, more than half of the patients were fine after discontinuing hydrocortisone replacement therapy. These results indicate that this unique type of hypothalamic AI has a curable clinical course making hydrocortisone replacement therapy a novel therapeutic option. Lippincott Williams & Wilkins 2022-10-14 /pmc/articles/PMC9575774/ /pubmed/36253985 http://dx.doi.org/10.1097/MD.0000000000030597 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4300
Takeshita, Kaori
Abe, Ichiro
Nagata, Mai
Ochi, Kentaro
Senda, Yuki
Koga, Midori
Ohe, Kenji
Abe, Makiko
Kudo, Tadachika
Kobayashi, Kunihisa
Clinical investigation of a unique type of hypothalamic adrenal insufficiency
title Clinical investigation of a unique type of hypothalamic adrenal insufficiency
title_full Clinical investigation of a unique type of hypothalamic adrenal insufficiency
title_fullStr Clinical investigation of a unique type of hypothalamic adrenal insufficiency
title_full_unstemmed Clinical investigation of a unique type of hypothalamic adrenal insufficiency
title_short Clinical investigation of a unique type of hypothalamic adrenal insufficiency
title_sort clinical investigation of a unique type of hypothalamic adrenal insufficiency
topic 4300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575774/
https://www.ncbi.nlm.nih.gov/pubmed/36253985
http://dx.doi.org/10.1097/MD.0000000000030597
work_keys_str_mv AT takeshitakaori clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT abeichiro clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT nagatamai clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT ochikentaro clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT sendayuki clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT kogamidori clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT ohekenji clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT abemakiko clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT kudotadachika clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency
AT kobayashikunihisa clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency